Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention

摘要: Objectives We investigated whether maintenance therapy with clopidogrel 150 mg/day produces greater platelet inhibition than the standard 75-mg/day dose and higher increases in low responders to 75 mg/day. Background Patients show interindividual variability their response clopidogrel. Low could potentially obtain clinical benefit from doses of Methods One hundred fifty-three elective percutaneous coronary intervention patients were randomized (n = 58) or 95) for 4 weeks, vasodilator-stimulated phosphoprotein assay-guided switching after 2 weeks (platelet reactivity index ≥69%). All received aspirin Results After produced a significantly lower (43.9 ± 17.3% vs. 58.6 17.7%; p l 0.0001). The proportion was those (8.6% 33.7%; 0.0004). In group, 64.5% (20 31) became weeks. No major bleeds occurred during study; incidence minor similar each treatment group. Conclusions patients, 150-mg/day function mg/day, overcomes responsiveness majority patients. These findings warrant further evaluation. (VASP-02; EudraCT number: 2004-005230-40).